Moderna's (NASDAQ: MRNA) $61.2 billion market cap is more than twice BioNTech's (NASDAQ: BNTX) $26 billion: a 2x floor implies $52 billion, leaving Moderna $9.2 billion above it. Both companies' financial results have deteriorated since pandemic-era peaks, and both have lagged broader equities over the past five years. The spread prices pipeline execution, specifically Moderna's recent late-stage wins against BioNTech's yet-to-be-validated candidates.
| Moderna (MRNA) | BioNTech (BNTX) | |
|---|---|---|
| Market cap (reported) | $61.2 billion | $26 billion |
| Key oncology late-stage win | Ph3: intismeran autogene (melanoma, with Merck) | None yet |
| Recent regulatory win | mFLUSIVA (U.S., influenza) | None |
| Notable setback | COVID franchise no longer growth driver | Ph2 autogene cevumeran halted |
Moderna's late-stage scorecard
Investor concern had centered on whether Moderna could generate meaningful revenue beyond the COVID-19 market. Intismeran autogene, an investigational personalized cancer vaccine developed with Merck (NYSE: MRK), directly addresses that concern: in phase 3, it meaningfully reduced the risk of recurrence in melanoma patients when added to Keytruda versus Keytruda alone. Moderna is testing the same vaccine across other potential indications in phase 2 and phase 3 studies. The company recently earned U.S. approval for mFLUSIVA, an influenza vaccine that outperformed existing approved flu vaccines in clinical trials and could help reduce hospitalizations and deaths among elderly patients, the population most exposed to severe disease. Moderna's coronavirus franchise is no longer a growth driver, but new approvals are expected to boost sales in the coming years.
BioNTech's data horizon
Pumitamig, co-developed with Bristol Myers Squibb (NYSE: BMY), is being tested across several potential indications including lung cancer, the leading cause of cancer death, and has been positioned as a potential challenger to Keytruda, the world's best-selling cancer drug marketed by Merck. More pumitamig data is projected within the next 18 months. That timeline comes alongside a recent setback: BioNTech halted a phase 2 trial of autogene cevumeran, an investigational mRNA cancer vaccine targeting colorectal cancer, after a recommendation from an independent group of experts reviewing clinical trial safety data. The company is also advancing a combined coronavirus and influenza vaccine and an HSV vaccine, but neither has produced late-stage results.
The $9.2 billion gap between Moderna's market cap and a simple 2x multiple of BioNTech's reflects the market's pricing of executed wins versus remaining potential. Pumitamig data, projected within 18 months, is the nearest catalyst that could shift that ratio.